Molecular adjuvant

Patent metadata

Field	Value
Publication number	US-2016304582-A1
Application number	US-201415101282-A
Country	US
Kind code	A1
Filing date	Dec 3, 2014
Priority date	Dec 4, 2013
Publication date	Oct 20, 2016
Grant date	—

Abstract

The invention relates to the use of a molecular adjuvant to generate an improved immune response in a host. Over recent years extensive research and development has been undertaken in the development of “vectored vaccines” which can be used as vaccine delivery systems. Vectored vaccines include DNA vectors and recombinant viral and bacterial vectors, which are engineered to express an antigen of interest. The invention provides a nucleic acid construct encoding a protein fusion between an antigen and an invariant chain molecule.

First claim

1 . A nucleic acid construct encoding a protein fusion between an antigen and a invariant chain molecule, said invariant chain molecule consisting of a fragment of SEQ ID NO: 1, a variant of SEQ ID NO: 1, a variant of a fragment of SEQ ID No: 1 or the peptide of SEQ ID NO.1, the said variants having at least 85% sequence identity with the corresponding portion of SEQ ID NO.1, wherein the invariant chain molecule produces an enhanced CD4 + and/or CD8 + and/or antibody immune response against the antigen upon immunisation with the construct compared to the CD4 + and/or CD8 + and/or antibody immune response obtained by immunisation with a control construct encoding the antigen not fused to the invariant chain molecule.

2 . A nucleic acid construct of claim 1 wherein the said invariant chain molecule consists of a fragment of SEQ ID NO.1 having:
(i) an N-terminus at any of positions 1 to 26 and a C-terminus at any of positions 72 to 87 of SEQ ID NO.1;
(ii) an N-terminus at positions 27 and a C-terminus at any of positions 72 to 75 or 77 to 87 of SEQ ID NO.1;
(iii) an N-terminus at positions 28 and a C-terminus at any of positions 72 to 74 or 78 to 87 of SEQ ID NO.1;
(iv) an N-terminus at positions 29 and a C-terminus at any of positions 72 to 73 or 79 to 87 of SEQ ID NO.1;
(v) an N-terminus at positions 30 and a C-terminus at any of positions 72 or 80 to 87 of SEQ ID NO.1;
(vi) an N-terminus at positions 31 and a C-terminus at any of positions 81 to 87 of SEQ ID NO.1;
(vii) an N-terminus at positions 32 and a C-terminus at any of positions 72 or 82 to 87 of SEQ ID NO.1;
(viii) an N-terminus at positions 33 and a C-terminus at any of positions 72 to 73 or 79 or 83 to 87 of SEQ ID NO.1;
(ix) an N-terminus at positions 34 and a C-terminus at any of positions 72 to 73 or 84 to 87 of SEQ ID NO.1;
(x) an N-terminus at positions 35 and a C-terminus at any of positions 72 or 85 to 87 of SEQ ID NO.1;
(xi) an N-terminus at positions 36 and a C-terminus at any of positions 86 to 87 of SEQ ID NO.1;
(xii) an N-terminus at positions 37 and a C-terminus at any of positions 72 or 87 of SEQ ID NO.1;
(xiii) an N-terminus at positions 38 and a C-terminus at any of positions 72 to 73 or 84 of SEQ ID NO.1;
(xiv) an N-terminus at positions 39 and a C-terminus at any of positions 72 to 74 or 78 of SEQ ID NO.1;
(xv) an N-terminus at positions 40 and a C-terminus at any of positions 72 to 75 or 77 of SEQ ID NO.1;
(xvi) an N-terminus at positions 41 and a C-terminus at any of positions 72 to 76 of SEQ ID NO.1;
(xvii) an N-terminus at positions 42 and a C-terminus at any of positions 72 to 77 of SEQ ID NO.1;
(xviii) an N-terminus at positions 43 and a C-terminus at any of positions 72 to 78 of SEQ ID NO.1;
(xix) an N-terminus at positions 44 and a C-terminus at any of positions 72 to 79 or 83 of SEQ ID NO.1;
(xx) an N-terminus at positions 45 and a C-terminus at any of positions 72 to 80 or 82 of SEQ ID NO.1;
(xxi) an N-terminus at positions 46 and a C-terminus at any of positions 72 to 81of SEQ ID NO.1;
(xxii) an N-terminus at positions 47 and a C-terminus at any of positions 72 to 82 of SEQ ID NO.1; or (xxiii) an N-terminus at any of positions 1 to 47 and a C-terminus at any of positions 97 or 98 of SEQ ID NO.1.

3 . A nucleic acid construct of claim 1 wherein said invariant chain molecule consists of:
(i) amino acids 1 to 72 of SEQ ID NO.1;
(ii) amino acids 47 to 98 of SEQ ID NO.1;
(iii) amino acids 47 to 72 of SEQ ID NO.1;
(iv) amino acids 16 to 98 of SEQ ID NO.1; or
(v) amino acids 16 to 72 of SEQ ID NO.1

4 . A nucleic acid construct of any preceding claim wherein the nucleic acid encoding the invariant chain molecule is replaced by a nucleic acid encoding a fragment of the invariant chain from a non-human species, such that the nucleic acid construct encodes a protein fusion between the antigen and a non-human invariant chain molecule, the said fragment of the invariant chain from a non-human species comprising the transmembrane domain of the full length invariant chain from that species.

5 . A nucleic acid construct of claim 4 wherein the encoded non-human invariant chain molecule is derived from the invariant chain from chicken, quail, trout, zebrafish, carp, frog, grouper, shark, mandarin fish or mallard.

6 . A nucleic acid construct of claim 5 wherein the encoded non-human invariant chain molecule is selected from:
(i) any of SEQ ID NO.s 2 to 12, 17 to 21; or
(ii) fragments of any of the sequences of SEQ ID NO.s 2 to 12, 17 to 21 comprising the transmembrane domain thereof; or
(iii) variants of the sequences in (i) or (ii) having at least 85% sequence identity therewith

the said fragments and variants producing an enhanced CD4 + and/or CD8 + and/or antibody immune response against the antigen upon immunisation with the construct compared to the CD4 + and/or CD8 + and/or antibody immune response obtained by immunisation with a control construct encoding the antigen not fused to the non-human invariant chain molecule.

7 . A nucleic acid construct of any preceding claim wherein the invariant chain molecule or non-human invariant chain molecule is a variant, and wherein the degree of sequence identity between the invariant chain molecule or non-human invariant chain molecule and the variant thereof is at least 90%, optionally at least 95%, preferably at least 96%, 97%, 98% or 99%.

8 . A nucleic acid construct of any preceding claim wherein the construct is a DNA vaccine.

9 . A nucleic acid construct of any of claims 1 to 7 wherein the construct is RNA.

10 . A nucleic acid construct of any of claims 1 to 7 wherein the construct is a viral vector, for example a viral vector derived from any of an adenovirus, such as chimpanzee adenoviruses, e.g. ChAdOx1 or ChAd63, a retrovirus, an alpha virus, an adeno-associated virus, a herpes virus, a vaccinia virus, a vaccinia derived virus e.g. MVA or NYVAC, a foamy virus, a cytomegalovirus, Semliki forest virus, a poxvirus, an avipox virus, e.g. canary pox or fowl pox, or an influenza virus, an RNA virus or a DNA virus.

11 . A nucleic acid construct of any preceding claim wherein the components of the protein fusion are separated by a peptide linker.

12 . A nucleic acid construct of any preceding claim wherein the antigen is derived from a pathogen.

13 . A nucleic acid construct of any preceding claim wherein the antigen is associated with cancer, an autoimmune disease or an allergy.

14 . A cell comprising a nucleic acid construct of any preceding claim, optionally wherein the cell is an antigen presenting cell.

15 . A pharmaceutical composition, e.g. a vaccine, comprising a nucleic acid construct of any of claims 1 to 13 or a cell of claim 14 and a pharmaceutically acceptable excipient.

16 . A nucleic acid construct of any of claims 1 to 13 , a cell of claim 14 or a composition of claim 15 for use in therapy by immunisation.

17 . A nucleic acid construct of any of claims 1 to 13 , a cell of claim 14 or a composition of claim 15 for use in the prevention or treatment of an infectious disease such as malaria, an autoimmune disease, allergy or cancer by immunisation.

18 . A method of eliciting an immune response comprising immunising a human or non-human animal with a nucleic acid construct of any of claims 1 to 13 , a cell of claim 14 or a composition of claim 15 .

19 . A method of claim 18 for the treatment or prevention of disease in a human or non-human patient.

20 . A non-therapeutic method of claim 18

Assignees

• Isis Innovation

Inventors

• Hill Adrian Vivian Sinton
• Spencer Alexandra J
• Halbroth Benedict R
• Cottingham Matthew G

Classifications

• C07K2319/00

  Fusion polypeptide · CPC title

• C12N2710/10043

  viral genome or elements thereof as genetic vector · CPC title

• C07K14/445

  Plasmodium · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K2039/55516

  Proteins; Peptides · CPC title